| Literature DB >> 34424711 |
Yongzhi Gao1, Matthijs J van Haren1, Ned Buijs1, Paolo Innocenti1, Yurui Zhang1, Davide Sartini2, Roberto Campagna2, Monica Emanuelli2, Richard B Parsons3, Willem Jespers4,5, Hugo Gutiérrez-de-Terán5, Gerard J P van Westen4, Nathaniel I Martin1.
Abstract
Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (vitamin B3) to generate 1-methylnicotinamide (MNA). NNMT overexpression has been linked to a variety of diseases, most prominently human cancers, indicating its potential as a therapeutic target. The development of small-molecule NNMT inhibitors has gained interest in recent years, with the most potent inhibitors sharing structural features based on elements of the nicotinamide substrate and the S-adenosyl-l-methionine (SAM) cofactor. We here report the development of new bisubstrate inhibitors that include electron-deficient aromatic groups to mimic the nicotinamide moiety. In addition, a trans-alkene linker was found to be optimal for connecting the substrate and cofactor mimics in these inhibitors. The most potent NNMT inhibitor identified exhibits an IC50 value of 3.7 nM, placing it among the most active NNMT inhibitors reported to date. Complementary analytical techniques, modeling studies, and cell-based assays provide insights into the binding mode, affinity, and selectivity of these inhibitors.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34424711 PMCID: PMC8436214 DOI: 10.1021/acs.jmedchem.1c01094
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446